SMO and basal cell carcinoma: In most basal cell carcinomas (BCCs) and medulloblastomas, loss-of-function mutations in PTCH and gain-of-function mutations in SMO both lead to ligand-independent, mutation-driven activation of the Hh pathway[44–46].